Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated

REVELATION BIOSCIENCES, INC.

Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).
Reduced cortical/medullary tubular necrosis and neutrophilic inflammation at 0.35 mg/kg dose.
Phase 1 clinical studies for Gemini initiated in February/March 2024.
Data presented at the 29th Intl Conference on Advances in Critical Care Nephrology on March 12, 2024.
Gemini is a synthetic TLR4 agonist that preconditions innate immunity to attenuate pro-inflammatory response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.